Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special drug use surveillance of Takecab (vonoprazan) for prevention of NSAID-associated peptic ulcer recurrence
jRCT1080223381Completed
- Sponsor
- Takeda
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vonoprazan in gastric ulcer, duodenal ulcer and Peptic ulcer disease (PUD), sponsored by Takeda. Primary endpoint: Safety of long-term vonoprazan use. Started Nov 2016; status: completed.
02
Drugs
vonoprazan
03
Conditions
gastric ulcerduodenal ulcerPeptic ulcer disease (PUD)
Beyond the preview
Go deeper on jRCT1080223381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223381.